Tabrecta® is the original global commercial brand name, and Tuoruidar is its Chinese brand name developed by Novartis. It is an oral highly selective MET tyrosine kinase inhibitor. It potently blocks MET receptor signaling to inhibit tumor cell proliferation and…
Ayvakit® is the commercial brand name of Avapritinib Tablets, developed by Blueprint Medicines. It is an oral highly selective inhibitor of KIT and PDGFRα kinases. It potently suppresses mutated KIT and PDGFRα signaling pathways, exerting anti-tumor activity against gastrointestinal stromal…
ITOVEBI® is the global commercial brand name, and Yihelai is its Chinese brand name developed by Roche. It is an oral third-generation highly selective PI3Kα inhibitor with dual inhibition and degradation mechanism. It specifically targets mutant PI3Kα protein to block…
Hyftor® is the global commercial brand name, and Xianluoli® is its Chinese brand name developed by Nobelpharma. It is a topical mTOR inhibitor gel. It locally inhibits abnormal mTOR pathway hyperactivation in skin lesions, reducing the size and redness of…
Mekinist® is the commercial brand name of Trametinib Tablets, developed by Novartis. It is an oral selective MEK1/MEK2 inhibitor. It blocks downstream MEK signaling of the RAS-RAF-MEK-ERK pathway, inhibiting proliferation of tumor cells carrying BRAF V600 mutations. Main IndicationsCombined therapy…
Camptosar® is the original international commercial brand name, while YimaiLin® is the domestic generic brand manufactured by Qilu Pharmaceutical. It is an injectable topoisomerase I inhibitor anti-tumor drug. It stabilizes the DNA-topoisomerase complex to induce DNA strand breaks and block…
Lonsurf® is the original global commercial brand name, and Suyuan® is its domestic generic brand manufactured by Qilu Pharmaceutical. It is an oral fixed-dose combined anti-tumor preparation. Trifluridine interferes with tumor DNA replication to inhibit cancer cell proliferation; tipiracil hydrochloride…
Livtencity® is the commercial brand name of Maribavir Tablets. It is an oral benzimidazole antiviral agent that inhibits human cytomegalovirus (CMV) DNA synthesis by targeting viral UL97 kinase, exerting potent activity against CMV strains resistant to traditional ganciclovir and foscarnet.…
Delstrigo® is the commercial brand name of Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, developed by MSD. It is a once-daily oral fixed-dose triple antiretroviral combination tablet. Doravirine inhibits HIV reverse transcriptase; lamivudine and tenofovir disoproxil fumarate block viral DNA…
Genvoya® is the international commercial brand name, and Jiefukang is its Chinese brand name. This fixed-dose four-component single-tablet antiretroviral regimen was developed by Gilead Sciences. Elvitegravir inhibits HIV integrase; cobicistat boosts elvitegravir exposure; emtricitabine and tenofovir alafenamide block viral reverse…